Abstract
Aims: Late treatment failure in chronic hepatitis C (CHC), defined as relapse during follow-up after an end-of-treatment response, occurs in up to 30% of patients treated with a standard combination therapy of pegylated IFN-alfa and ribavirin (Caliceti P, Dig Liver Dis 2004; 36, Suppl. 3: 334–339). Thus far, only hcv-genotype, age, dose of ribavirin and duration of infection have been proposed as predictors of relapse. We sought to identify other potential predictors of relapse in genotype-1 patients who received weight-based PegIFN-alfa-2b and ribavirin within a large ongoing German multicentre observational study.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call